Sacituzumab govitecan (SG) is a novel antibody–drug conjugate used to treat advanced breast cancer, particularly in patients with a metastatic triple-negative (mTNBC) or metastatic hormone receptor-positive/HER2-negative (mHRPBC) subtype who have limited treatment options. This evidence concerns the gene NR4A1 and breast cancer.